ATE437220T1 - Verwendung von interleukin-17 für oozytenreifung - Google Patents

Verwendung von interleukin-17 für oozytenreifung

Info

Publication number
ATE437220T1
ATE437220T1 AT05806042T AT05806042T ATE437220T1 AT E437220 T1 ATE437220 T1 AT E437220T1 AT 05806042 T AT05806042 T AT 05806042T AT 05806042 T AT05806042 T AT 05806042T AT E437220 T1 ATE437220 T1 AT E437220T1
Authority
AT
Austria
Prior art keywords
interleukin
oocyte maturation
vitro
maturation
oocytes
Prior art date
Application number
AT05806042T
Other languages
English (en)
Inventor
Matos Daniel De
Cam Anh Tran
Ann Clark
Stephen Palmer
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35529384&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE437220(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE437220T1 publication Critical patent/ATE437220T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pregnancy & Childbirth (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT05806042T 2004-09-30 2005-09-30 Verwendung von interleukin-17 für oozytenreifung ATE437220T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61466704P 2004-09-30 2004-09-30
PCT/US2005/035372 WO2006039592A1 (en) 2004-09-30 2005-09-30 Use of il-17- for maturation of oocytes

Publications (1)

Publication Number Publication Date
ATE437220T1 true ATE437220T1 (de) 2009-08-15

Family

ID=35529384

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05806042T ATE437220T1 (de) 2004-09-30 2005-09-30 Verwendung von interleukin-17 für oozytenreifung

Country Status (11)

Country Link
US (1) US20070231896A1 (de)
EP (1) EP1794287B1 (de)
JP (1) JP5188806B2 (de)
AT (1) ATE437220T1 (de)
AU (1) AU2005292362B2 (de)
CA (1) CA2578573C (de)
DE (1) DE602005015599D1 (de)
ES (1) ES2329393T3 (de)
IL (2) IL181908A (de)
NO (1) NO20072245L (de)
WO (1) WO2006039592A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112048017B (zh) * 2019-09-03 2021-04-20 南京市妇幼保健院 一种卵母细胞体外成熟培养方法
CN113403259B (zh) * 2021-06-04 2023-01-17 华南农业大学 一种提高克隆胚胎发育质量的添加剂及其应用
CN113249305A (zh) * 2021-06-04 2021-08-13 华南农业大学 卵母细胞体外成熟培养液添加剂、培养液及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169835A (en) * 1989-01-18 1992-12-08 Oklahoma Medical Research Foundation Pregancy specific proteins applications
US20030124092A1 (en) * 2001-06-21 2003-07-03 Eugene Medlock IL-17 like molecules and uses thereoflike molecules and uses thereof
EP1215280A1 (de) * 2000-12-13 2002-06-19 Vrije Universiteit Brussel Verfahren zur in Vitro-Kultivierung von Ovarfollikulen
WO2003076600A2 (en) * 2002-03-08 2003-09-18 Mcgill University In vitro maturation of immature human oocytes
JP2008501035A (ja) * 2004-05-28 2008-01-17 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 妊孕性関連障害の治療におけるｉｌ−１７の使用

Also Published As

Publication number Publication date
EP1794287A1 (de) 2007-06-13
IL181908A0 (en) 2007-07-04
US20070231896A1 (en) 2007-10-04
CA2578573A1 (en) 2006-04-13
WO2006039592A1 (en) 2006-04-13
ES2329393T3 (es) 2009-11-25
JP5188806B2 (ja) 2013-04-24
IL181908A (en) 2010-11-30
IL206440A0 (en) 2010-12-30
CA2578573C (en) 2015-02-03
WO2006039592A9 (en) 2006-07-27
EP1794287B1 (de) 2009-07-22
AU2005292362A1 (en) 2006-04-13
JP2008514238A (ja) 2008-05-08
DE602005015599D1 (de) 2009-09-03
AU2005292362B2 (en) 2012-05-31
NO20072245L (no) 2007-04-30

Similar Documents

Publication Publication Date Title
EA200802213A1 (ru) Способы лечения заболеваний крови
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
DE60142031D1 (de) Viskoelastische substanzen zur verwendung bei mittelohr operationen
DE602004030334D1 (de) Synthese von 5-substituierten 7-azaindolen und 7-azaindolinen
EA200802054A1 (ru) Ингибиторы фермента
IL189542A (en) In vitro methods to alter the stability of proteins including fc for fission through proteases
EA200801716A1 (ru) Тиазольные соединения и их применение
NO20071127L (no) Triazoloftalaziner
CR7977A (es) Anilidas de acido trifluorometil-tiofencarboxilico y su uso como fungicidas
NZ569543A (en) Means and methods for influencing the stability of antibody producing cells
DE602005025988D1 (de) Zwischenprodukte für die herstellung von pramipexol
NO20055741D0 (no) Nye kjemiske forbindelser
ATE445402T1 (de) Neue verwendung von pde5-hemmern
IL206440A0 (en) Use of il-17 for maturation of oocytes
ATE548446T1 (de) Herstellung und reinigung von protein a ohne die verwendung von tierischen komponenten
TW200738752A (en) Modulation of MDL-1 activity for treatment of inflammatory disease
NO20062949L (no) Anvendelse av cytokiner av IL-6-typen for modning av oocytter
ATE483016T1 (de) Biologische materialien und verwendungen davon
MX2007002833A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios.
MX2007003398A (es) Sulfonamidas y sus usos.
ATE344828T1 (de) Azofarbstoffe
ATE392413T1 (de) Verfahren zur herstellung von beta-alaninamiden
WO2005023980A3 (en) Use of complement protein c3 and its derivatives in enhancing mammalian embryo development
DE602007009413D1 (de) Sitamaquintosylat zur behandlung von leishmaniase
EA200701236A1 (ru) 3-циклопропил-4-(3-амино-2-метилбензоил)пиразолы и их применение в качестве гербицидов

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties